-
公开(公告)号:PT730473E
公开(公告)日:2002-02-28
申请号:PT95901432
申请日:1994-11-25
Applicant: BASF AG
Inventor: ECKES PETER , SCHWEDEN JURGEN , WILFRIED HORNBERGER , SUBKOWSKI THOMAS
Abstract: PCT No. PCT/EP94/03901 Sec. 371 Date May 31, 1996 Sec. 102(e) Date May 31, 1996 PCT Filed Nov. 25, 1994 PCT Pub. No. WO95/15183 PCT Pub. Date Jun. 8, 1995The invention relates to novel hirudin conjugates formed from a hirudin and one or more lipophilic compounds, where the lipophilic compound has an octanol/water partition coefficient of more than 1.8 and is chemically linked to the hirudin, to the preparation thereof and to the use thereof.
-
公开(公告)号:HK1049001A1
公开(公告)日:2003-04-25
申请号:HK03101187
申请日:2003-02-18
Applicant: BASF AG
Inventor: ANDREAS KLING , HERVE GENESTE , UDO LANGE , ARNULF LAUTERBACH , CLAUDIA ISABELLA GRAEF , THOMAS SUBKOWSKI , UTA HOLZENKAMP , HELMUT MACK , JENS SADOWSKI , WILFRIED HORNBERGER , VOLKER LAUX
IPC: C07D20060101 , A61K20060101 , A61K31/4402 , A61K31/55 , A61K31/5513 , A61P20060101 , A61P3/14 , A61P5/18 , A61P7/02 , A61P9/00 , A61P9/08 , A61P9/10 , A61P9/12 , A61P9/14 , A61P13/12 , A61P17/02 , A61P17/06 , A61P19/00 , A61P19/08 , A61P19/10 , A61P29/00 , A61P31/04 , A61P31/12 , A61P33/00 , A61P35/00 , A61P35/04 , A61P43/00 , C07D213/74 , C07D223/20 , C07D243/38 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/12 , C07D409/14 , C07D417/06 , C07D417/12 , C07D417/14 , C07D471/04 , C07D495/04 , C07D495/14
-
公开(公告)号:MXPA02003419A
公开(公告)日:2002-10-17
申请号:MXPA02003419
申请日:2000-10-02
Applicant: BASF AG
Inventor: WILFRIED HORNBERGER
IPC: A61K38/00 , A61K45/00 , A61K45/06 , A61P9/00 , A61P9/08 , A61P9/10 , A61P19/02 , A61P29/00 , A61P37/06 , A61P43/00 , C07D239/34 , C07D263/34 , C07D277/48 , C07D307/68 , C07D333/38 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/12 , C07D417/12 , C07D417/14 , C07K5/02
Abstract: La invencion se refiere al uso de moduladores de las vias de senalizacion mediadas por citocinas en combinacion con antagonistas de los receptores para integrina ?v?3 para el tratamiento o prevencion de enfermedades, en particular al uso de una composicion farmaceutica que contiene un modulador de las vias de senalizacion mediadas por citocinas y un antagonista de los receptores para integrina ?v?3 para el tratamiento o prevencion de trastornos inflamatorios o auto-inmunes, en particular para el tratamiento o prevencion de artritis reumatoide, y a la propia composicion farmaceutica.
-
-